spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  non-small cell lung cancer 


 Your search returned too many results! The most recent 500 items are shown below:
 HSMN NewsFeed - 18 Nov 2024
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Feb 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jan 2024
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Dec 2023
Amgen Provides Regulatory Update on Status of Lumakras(R) (Sotorasib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2023
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jul 2022
Nuvalent Announces Leadership Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 May 2022
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 18 May 2022
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 May 2022
Phosplatin Therapeutics Adopts New Corporate Name as Promontory Therapeutics Inc.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Mar 2022
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2022
Biofidelity Raises $23M in Series A+ Financing led by Octopus Ventures to Launch ASPYRE Technology
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 13 Jan 2022
SK Life Science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Dec 2021
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 13 Dec 2021
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control(R) Platform
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2021
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 1 Nov 2021
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Aug 2021
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 May 2021
Olympus Announces New Endobronchial Ultrasound (EBUS) Bronchoscope
Devices Product Launch
 HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Apr 2021
Amgen Launches Biomarker Assist(TM), a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 13 Apr 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2021
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
Diagnostics Oncology FDA
 HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2021
Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 21 Dec 2020
Servier to Acquire Agios Pharmaceuticals' Oncology Business
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 8 Dec 2020
Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Oct 2020
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 25 Aug 2020
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 May 2020
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 1 Apr 2020
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2020
ArcherDX Receives Approval for Archer(R)MET Companion Diagnostic for TEPMETKO(R) (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 24 Mar 2020
Apexigen Completes $123 Million Series C Financing To Advance Clinical Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 9 Mar 2020
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Dec 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Nov 2019
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2019
Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor
Diagnostics Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 Sep 2019
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2019
Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2019
IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win(R) Immunotherapy in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Feb 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 23 Nov 2018
Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore
Diagnostics Oncology
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Aug 2018
Roche receives FDA approval for cobas EGFR Mutation Test v2 as companion diagnostic with IRESSA (gefitinib) in first-line treatment of patients with non-small cell lung cancer (NSCLC)
Diagnostics Oncology FDA
 HSMN NewsFeed - 8 Aug 2018
Apexigen Raises $73 Million In Series B And Series C Financings
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2018
PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2018
Alpha Biopharma Announces Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 May 2018
Genprex Announces $10 Million Private Placement
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 11 Apr 2018
Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy
Biopharmaceuticals Oncology Drug Delivery Personnel
 HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Dec 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Nov 2017
Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jul 2017
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
Regenerative Medicine Neurology
 HSMN NewsFeed - 1 Jun 2017
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
Diagnostics Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2017
New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
Regenerative Medicine Neurosurgery
 HSMN NewsFeed - 26 Apr 2017
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Feb 2017
Syndax Appoints Richard P. Shea as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Nov 2016
Athenex and Lilly Enter Clinical Collaboration Agreement
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2016
Turnstone Biologics Raises $41.4 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Oct 2016
Agilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer (NSCLC)
Diagnostics Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Aug 2016
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement
Biopharmaceuticals Wound Care Mergers & Acquisitions
 HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2016
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Apr 2016
Hematogenix Laboratory Services, LLC (Hematogenix)- Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immuno-Oncology Therapies
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA
 HSMN NewsFeed - 17 Mar 2016
Allergan Confirms Generic Abraxane(R) Patent Challenge
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 16 Feb 2016
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of Anamorelin in Northern Europe Countries
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 29 Jan 2016
Helix BioPharma Corp. Announces Appointment of New Directors to the Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 20 Jan 2016
Allan L. Shaw Joins Syndax Pharmaceuticals As Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Dec 2015
Eagle Pharmaceuticals Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2015
Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Dec 2015
Nemucore Medical Innovations Completes Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2015
Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2015
CureVac raises $110 Million in a private placement
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 30 Oct 2015
Celgene’s VIDAZA(R) (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2015
Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Oct 2015
Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Oct 2015
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2015
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Biopharmaceuticals Oncology Dermatology
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2015
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Sep 2015
Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Sep 2015
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of anamorelin in Switzerland and Liechtenstein
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2015
AstraZeneca Provides Update On Selumetinib In Uveal Melanoma
Biopharmaceuticals Oncology Ophthalmology
 HSMN NewsFeed - 14 Jul 2015
New TomoTherapy(R) System Data Presented at Leading Scientific Industry Meeting
Devices Oncology
 HSMN NewsFeed - 14 Jul 2015
Biocept Launches Diagnostic Assay for BRAF Mutations in Patients with Melanoma
Diagnostics Personalized Medicine Oncology Product Launch
 HSMN NewsFeed - 11 Jun 2015
Personal Genome Diagnostics Launches LungSelect(TM) For Non-Invasive Detection Of Clinically Actionable Mutations In Lung Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 May 2015
Transgenomic Launches EGFR CLIA Test That Accurately Detects Key Mutations in Solid and Liquid Patient Samples Using Multiplexed ICE COLD-PCR(TM)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 12 May 2015
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 27 Apr 2015
Synta Announces Chen Schor Named President, Chief Executive Officer and Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Apr 2015
Oasmia's Lead Cancer Product Paclical(R) Receives Market Approval in the Russian Federation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Mar 2015
Tyrogenex, Xcovery Appoint Michael Webb as President and Chief Executive Officer
Biopharmaceuticals Ophthalmology Oncology Personnel
 HSMN NewsFeed - 20 Mar 2015
Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2015
Coronado Biosciences Announces Exclusive Licensing Agreement With NeuPharma to Develop and Commercialize Novel Covalent 3rd Generation EGFR Inhibitors
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Mar 2015
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Feb 2015
Biodesix Builds on Investments in Sales, Reimbursement and Government Affairs Growth Strategy
Diagnostics Personnel
 HSMN NewsFeed - 12 Feb 2015
Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2014
BIND Therapeutics Appoints Two New Board Members
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Aug 2014
FDA Approves Genentech’s Avastin Plus Chemotherapy for Treatment of Advanced Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Aug 2014
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jul 2014
FDA Grants Genentech’s Avastin Priority Review for Certain Types of Cervical Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jul 2014
Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2014
Aduro Announces License Agreement with Johnson & Johnson Innovation for Novel Immunotherapies for Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2014
Agios Pharmaceuticals Appoints Chris Bowden, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Apr 2014
Merck Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2014
GTx Announces Departure of CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Mar 2014
FDA Approves Optiguide(R) DCYL700 Fiber Optic Diffuser Series Flexible Fiber
Devices FDA
 HSMN NewsFeed - 21 Mar 2014
 Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT(R) (vintafolide) and Companion Imaging Agents FOLCEPRI(R) (etarfolatide) and NEOCEPRI(R) (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer
Biopharmaceuticals Oncology Radiology Regulatory
 HSMN NewsFeed - 11 Mar 2014
Exosome Diagnostics Raises $27 Million in Series B Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2014
Heat Biologics, Inc. Appoints Taylor H. Schreiber, M.D., PH.D. as Vice President of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2014
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2014
Novocure Enrolls First Patient in Pilot Clinical Trial of NovoTTF(TM) Therapy Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Adenocarcinoma
Devices Oncology
 HSMN NewsFeed - 15 Jan 2014
AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jan 2014
Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 7 Jan 2014
BIND Therapeutics Announces Departure of Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jan 2014
Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Dec 2013
Concordia Healthcare Corp. Announces Acquisition Of Pinnacle Biologics, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 17 Dec 2013
Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Dec 2013
Biodesix Closes Series E Financing
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 27 Nov 2013
Study Suggests Non-Invasive Stereotactic Ablative Body Radiotherapy May Be Suitable Alternative to Surgery for Early-Stage Lung Cancer Patients
Devices Oncology
 HSMN NewsFeed - 19 Nov 2013
Novocure Enrolls First Patients in a Randomized Trial of NovoTTF(TM) Therapy for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Devices Oncology
 HSMN NewsFeed - 25 Sep 2013
Heat Biologics Appoints Louis C. Bock to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Sep 2013
U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2013
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 24 Jul 2013
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jul 2013
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2013
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2013
Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2013
Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx(R)
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 3 Jan 2013
NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Nov 2012
Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
Devices Oncology
 HSMN NewsFeed - 12 Nov 2012
Clovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2012
Varian Medical Systems Highlights a Comprehensive Product Portfolio for the Non-Invasive Treatment of Lung Cancer
Devices Oncology
 HSMN NewsFeed - 24 Oct 2012
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2012
Varian Medical Systems to Support an NCI-Sponsored Phase III Study Comparing Radiosurgery with Surgery for the Treatment of Early-Stage High-Risk, Operable Non-Small Cell Lung Cancer
Devices Oncology Surgery
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2012
Biodesix Appoints Vice President of Clinical Development & Medical Affairs
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 26 Jun 2012
Caris Life Sciences Launches Caris Target Now(TM) Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary
Diagnostics Oncology
 HSMN NewsFeed - 19 Jun 2012
Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI(R) (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2012
Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
Devices Oncology
 HSMN NewsFeed - 1 May 2012
Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Devices Oncology
 HSMN NewsFeed - 27 Mar 2012
Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2012
Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 15 Dec 2011
Cerulean Pharma Closes $15 Million Series D Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 Nov 2011
Curis Announces Appointment of Maurizio Voi, M.D. as Chief Medical and Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2011
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jul 2011
Agennix Hires Christine Boisclair as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jun 2011
Agennix Hires Jill Porter as Senior Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jun 2011
TESARO Announces $101 Million Series B Financing for Advancement and Expansion of Oncology Product Portfolio
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 15 Jun 2011
Endocyte Names Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 May 2011
Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
Devices Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 May 2011
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2011
TESARO Enters into Exclusive License Agreement with Amgen to Acquire Rights to Anaplastic Lymphoma Kinase (ALK) Program
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jan 2011
CyberKnife Radiosurgery to be Highlighted by Leading Thoracic Surgeons at 2011 STS Annual Meeting
Devices Oncology
 HSMN NewsFeed - 26 Jan 2011
APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 10 Jan 2011
Exelixis’ XL184 Granted Orphan Drug Designation and Assigned the Generic Name Cabozantinib
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2010
Lilly Suspends Phase III Trial in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2010
New Multiple Myeloma Treatment Guidelines for Patients Available from NCCN
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Dec 2010
US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Nov 2010
VeriStrat(R) Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 15 Nov 2010
Cerulean Pharma Inc. Closes $24 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2010
OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Sep 2010
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2010
Complex Lung Cancer Treatments Delivered Successfully at Leading Varian-Equipped Proton Therapy Center
Devices Oncology
 HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jun 2010
Exelixis Regains Full Rights to Develop and Commercialize XL184
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2010
Lorus Therapeutics Files Investigational New Drug Application With FDA for Anticancer Drug LOR-253
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2010
Study Reveals TomoTherapy(R) Technology Plays Key Role in Enabling Concurrent Chemo-Radiation Treatments for Lung Cancer
Devices Oncology
 HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2010
Asuragen Appoints French Distributor Biomedical Diagnostics SA for Signature(R) Oncology Portfolio
Diagnostics Oncology Distribution
 HSMN NewsFeed - 19 Mar 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2010
Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy
Diagnostics Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2010
BSD Medical Reports Publication of Chinese Study Using the BSD-2000 Hyperthermia System to Treat Lung Cancer
Devices Oncology
 HSMN NewsFeed - 11 Feb 2010
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2010
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2009
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Nov 2009
Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2009
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Nov 2009
NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Biopharmacetuicals Onocology
 HSMN NewsFeed - 16 Oct 2009
Endocyte Officials Announce Close of $26 Million Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Sep 2009
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2009
FDA Approves Avastin for the Most Common Type of Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2009
AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2009
ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2009
Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2009
Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jun 2009
Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2009
ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticasl Oncology Regulatory
 HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 May 2009
Biodesix Advances the Field of Personalized Medicine With the Launch of VeriStrat(R)
Diagnostics Oncology
 HSMN NewsFeed - 24 Apr 2009
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Apr 2009
Encouraging Results Published on Use of TomoTherapy in Lung Cancer Treatment
Devices Oncology
 HSMN NewsFeed - 2 Apr 2009
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2009
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2008
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2008
NovaRx Appoints Industry Veteran as President and COO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Oct 2008
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Sep 2008
Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2008
Onyx Pharmaceuticals Names Juergen Lasowski, Ph.D. as Senior Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2008
Emerging Clinical Data Continues to Support CyberKnife Radiosurgery for the Treatment of Lung Cancer
Devices Oncology
 HSMN NewsFeed - 5 Aug 2008
New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
Devices Oncology
 HSMN NewsFeed - 5 Aug 2008
Telik Names Stefan Ryser, Ph.D. Senior Vice President, Corporate Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2008
Lung Cancer Epidemic Looming in Asia?
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jul 2008
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2008
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2008
Sonus Pharmaceuticals and OncoGenex Technologies to Merge
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 May 2008
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 May 2008
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Apr 2008
Alfacell Announces Retirement of Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2008
Amrubicin is Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Apr 2008
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Apr 2008
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Mar 2008
Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Mar 2008
BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
Novelos Therapeutics Reaches Target Enrollment in Pivotal Phase 3 Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
Diagnostics Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2008
Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2008
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2008
Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2008
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2008
Dr. Thomas Okarma Resumes Direct Leadership of Geron's Oncology Drug Development Activities
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jan 2008
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement With BL&H for South Korea, Taiwan and Hong Kong
Biopharmaceuticals Distribution Oncology
 HSMN NewsFeed - 17 Jan 2008
Alfacell Appoints David Sidransky Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jan 2008
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 Dec 2007
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2007
Antisoma opens US Headquarters in Princeton, New Jersey
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2007
Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Dec 2007
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2007
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Dec 2007
Genentech Provides Update from Avastin FDA Advisory Meeting
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Dec 2007
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Nov 2007
Alfacell Appoints Lawrence A. Kenyon Chief Operating Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2007
Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2007
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Non-Small Cell Lung Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Oct 2007
Abraxis BioScience and Biocon Limited Announce Approval of ABRAXANE in India for the Treatment of Breast Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2007
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2007
OSI Pharmaceuticals Provides Additional Information about US Sales of Tarceva
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2007
Abraxis Bioscience Reaches Agreement with the FDA Following Special Protocol Assessment for Phase III Trial of ABRAXANE in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2007
Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Oct 2007
ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Sep 2007
Biomira announces plan to change name to Oncothyreon
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2007
CuraGen Appoints Clinical Oncologist as VP of Medical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2007
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmacetuicals Oncology
 HSMN NewsFeed - 20 Sep 2007
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Sep 2007
CG Therapeutics Appoints Dr. Christopher S. Henney as Chairman of Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2007
Pharmacyclics Announces Addition of Robert W. Duggan to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2007
Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Sep 2007
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2007
Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Aug 2007
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Aug 2007
GlaxoSmithKline Accelerates Review of Exelixis' XL880
Biopharmaceuticals
 HSMN NewsFeed - 22 Aug 2007
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Biopharmaceuticals
 HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 12 Jul 2007
Point Therapeutics Update
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jul 2007
Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jun 2007
Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
OSI Pharmaceuticals Begins Clinical Development Program of OSI-906 in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2007
FDA Converts TELCYTA Full Clinical Hold to Partial Hold
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jun 2007
OSI Pharmaceuticals Announces the Election of Kenneth B. Lee, Jr. to Its Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jun 2007
Biodesix, Inc. Announces Breakthrough In Molecular Diagnostics For Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 5 Jun 2007
Encouraging Clinical Activity of GSK's Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
XYOTAX(TM) More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pre-menopausal Estrogen Levels Linked to Higher Death Rate Among Women Receiving Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Telik Reports Results of TELCYTA(R) Assist-3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Telik Announces Top-Line Results of TELCYTA(R) ASSIST-2 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Telik Reports Results of TELCYTA(R) ASSIST-1 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Point Therapeutics Reduces Costs by Cutting Work Force
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 21 May 2007
Talabostat Clinical Program Put on Clinical Hold by FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2007
Tapestry Pharmaceuticals Announces Phase II Clinical Program for TPI 287
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2007
Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients with Advanced Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2007
Pharmacyclics Announces FDA Filing of New Drug Application for Xcytrin(R) Injection to Treat Lung Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2007
ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of TELCYTA as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
Biopharmacetuicals Oncology
 HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Cell Therapeutics, Inc. (CTI) Announces XYOTAX(TM) Has Fast Track Designation for Women With Advanced Lung Cancer Who Are Performance Status 2 (PS2)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2007
Coley Pharmaceutical Group Announces Completion of Patient Enrollment in Pfizer's Two Pivotal Phase III NSCLC Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2007
Researchers Identify Intracellular Pathway of Alfacell's ONCONASE(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Pharmacyclics' Xcytrin New Drug Application for Treatment of Lung Cancer Brain Metastases to Be Filed Over Protest
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Mar 2007
Protox Announces Senior Management Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Mar 2007
Endocyte Secures $15 Million in Series C-3 Round of Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Mar 2007
Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's ONCONASE(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
Cell Therapeutics Inc. (CTI) Files for Special Protocol Assessment (SPA) for XYOTAX(TM) PGT307 Lung Cancer Trial in Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2007
Point Therapeutics Provides Clinical Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Feb 2007
Pharmacyclics Receives Refuse to File Letter for Xcytrin
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Feb 2007
Tapestry Pharmaceuticals Appoints Sandra L. Silberman, M.D., Ph.D. As Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jan 2007
Alfacell Appoints David Sidransky M.D. as Vice Chairman and Lead Independent Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jan 2007
NCCN Updates Non-Small Cell Lung Cancer Guidelines
Devices Radiology Oncology
 HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2007
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jan 2007
Alfacell Appoints Lawrence A. Kenyon as Executive Vice President, Chief Financial Officer and Corporate Secretary
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jan 2007
Vicus Therapeutics Announces the FDA has Allowed the Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Biopharmaceuticals
 HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jan 2007
OSI Pharmaceuticals Licenses Its Glucokinase Activator Program for the Treatment of Type 2 Diabetes to Eli Lilly and Company
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 2 Jan 2007
Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer now open for patient enrollment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Dec 2006
Tapestry Pharmaceuticals Appoints Donald H. Picker, Ph.D. As President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Dec 2006
Telik Reports Preliminary Results on ASSIST-1, ASSIST-2 and ASSIST-3 Phase 3 Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Dec 2006
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Dec 2006
Pharmacyclics Submits New Drug Application for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2006
Alfacell Corporation Files for U.S. Orphan Drug Designation for ONCONASE(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2006
Alfacell Corporation and GENESIS Pharma S.A. Announce Exclusive Licensing Agreement for ONCONASE in Southeast Europe
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Dec 2006
OSI Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Dec 2006
OSI Pharmaceuticals Grants License to Bristol-Myers Squibb under Dipeptidyl Peptidase IV (DPIV) Patent Portfolio for the Treatment of Type 2 Diabetes
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Dec 2006
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Biomira receives special protocol assessment from the FDA for Phase III trial of Stimuvax for non-small cell lung cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Nov 2006
Pharmacyclics Announces Presentation of Pooled Analysis of Xcytrin(R) for Lung Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2006
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions
Return to NewsFeed  

 Additional items found! 489

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 489 additional stories matching:
non-small cell lung cancer
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.